6B8CAF74-45C6-4C20-8126-A99F73346198
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 15.440210249671484
- age_years
- 53
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.647
- E2F_TARGETS+0.646
- MYC_TARGETS_V1+0.645
- MYC_TARGETS_V2+0.600
- G2M_CHECKPOINT+0.578
- INTERFERON_GAMMA_RESPONSE+0.551
- TNFA_SIGNALING_VIA_NFKB+0.516
- DNA_REPAIR+0.505
- UNFOLDED_PROTEIN_RESPONSE+0.440
- MTORC1_SIGNALING+0.439
Top 10 suppressed
- KRAS_SIGNALING_DN-0.301
- MYOGENESIS-0.234
- APICAL_SURFACE-0.175
- SPERMATOGENESIS-0.151
- HEDGEHOG_SIGNALING-0.085
- BILE_ACID_METABOLISM-0.072
- APICAL_JUNCTION-0.057
- ESTROGEN_RESPONSE_LATE-0.007
- ESTROGEN_RESPONSE_EARLY+0.001
- HEME_METABOLISM+0.008
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | EB8F7B74-694A-4F9F-9C0B-F04006033CA4 | — | — | 0.971 |
| 2 | C14BEAAE-A766-4ADE-A9B4-674D8717591F | — | — | 0.965 |
| 3 | 93A7AA5D-FA07-470A-9FD3-306EA577D3C4 | — | — | 0.964 |
| 4 | 812834CD-DA8F-4C0C-A49E-31D4A882D0E0 | — | — | 0.952 |
| 5 | 1B940F72-3C90-43C4-9267-185F21D10AC9 | — | — | 0.949 |
| 6 | D494D692-9EC2-429A-A0FE-696D2A152D4A | — | — | 0.947 |
| 7 | BB96C5BA-CA50-40B4-B22A-3FCFE46AB11C | — | — | 0.947 |
| 8 | 55E3F1FB-D55D-42F8-A9E1-7828F7BFF595 | — | — | 0.946 |
| 9 | 94640BD8-E1D9-482D-A597-4790F6EEA6B7 | — | — | 0.945 |
| 10 | 1B326CC6-3916-4D1D-A238-7B3C42F3E6C6 | — | — | 0.945 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.647 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.646 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.645 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.578 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.551 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.516 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.505 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.440 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.439 | Inavolisib | — uncovered |
| APOPTOSIS | 0.389 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.378 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.374 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.343 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.342 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.326 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.317 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.294 | Inavolisib | — uncovered |
| HYPOXIA | 0.280 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.280 | Inavolisib | — uncovered |